Eur J Clin Invest 2021 Apr 9:e13571. Epub 2021 Apr 9.
The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), Berlin, Germany.
Pulmonary hypertension (PH), and especially pulmonary arterial hypertension (PAH), are chronic, progressive, and fatal conditions for which - apart from bilateral lung transplantation - there is currently no cure. However, recently developed, so-called "targeted" ("advanced") PAH medications, are now approved for adult PAH, and have improved quality of life and survival of affected children and adults. In 2020, two prospective pediatric observational studies on add-on macitentan and selexipag, respectively, have been published. Read More